Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

MLA

van Zandwijk, Nico, et al. “Safety and Activity of MicroRNA-Loaded Minicells in Patients with Recurrent Malignant Pleural Mesothelioma: A First-in-Man, Phase 1, Open-Label, Dose-Escalation Study.” Lancet Oncology, vol. 18, no. 10, Oct. 2017, pp. 1386–96. EBSCOhost, https://doi.org/10.1016/S1470-2045(17)30621-6.

APA

van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M. J., Bailey, D. L., Cooper, W. A., Kritharides, L., Ridley, L., Pattison, S. T., MacDiarmid, J., Brahmbhatt, H., & Reid, G. (2017). Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncology, 18(10), 1386–1396. https://doi.org/10.1016/S1470-2045(17)30621-6

Chicago

van Zandwijk, Nico, Nick Pavlakis, Steven C Kao, Anthony Linton, Michael J Boyer, Stephen Clarke, Yennie Huynh, et al. 2017. “Safety and Activity of MicroRNA-Loaded Minicells in Patients with Recurrent Malignant Pleural Mesothelioma: A First-in-Man, Phase 1, Open-Label, Dose-Escalation Study.” Lancet Oncology 18 (10): 1386–96. doi:10.1016/S1470-2045(17)30621-6.